Novo Nordisk A/S (NYSE:NVO) Upgraded at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Novo Nordisk A/S (NYSE:NVO) from an underperform rating to a market perform rating in a research report released on Monday morning, Marketbeat.com reports.

Several other equities research analysts also recently issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Trading Up 2.7 %

NVO opened at $85.63 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company’s 50-day moving average is $101.38 and its 200 day moving average is $120.03. The firm has a market capitalization of $384.27 billion, a PE ratio of 27.71, a P/E/G ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVO. Rhumbline Advisers grew its holdings in Novo Nordisk A/S by 0.4% during the second quarter. Rhumbline Advisers now owns 60,974 shares of the company’s stock valued at $8,703,000 after purchasing an additional 270 shares during the period. Savant Capital LLC increased its holdings in Novo Nordisk A/S by 16.2% in the 2nd quarter. Savant Capital LLC now owns 12,587 shares of the company’s stock worth $1,797,000 after acquiring an additional 1,751 shares during the last quarter. Strategic Financial Concepts LLC raised its stake in Novo Nordisk A/S by 12,106.7% in the 2nd quarter. Strategic Financial Concepts LLC now owns 206,172 shares of the company’s stock valued at $294,000 after acquiring an additional 204,483 shares during the period. Chris Bulman Inc purchased a new stake in Novo Nordisk A/S during the second quarter valued at about $71,000. Finally, Certuity LLC boosted its position in Novo Nordisk A/S by 83.6% during the second quarter. Certuity LLC now owns 4,416 shares of the company’s stock worth $630,000 after purchasing an additional 2,011 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.